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Abstract: Vulvovaginal atrophy (VVA) and dryness are common symptoms of the decline in 
endogenous production of estrogen at menopause and often result in dyspareunia. Yet while 
10% to 40% of women experience discomfort due to VVA, it is estimated that only 25% seek 
medical help. The main goals of treatment for vaginal atrophy are to improve symptoms and to 
restore vaginal and vulvar anatomic changes. Treatment choices for postmenopausal dyspareunia 
resulting from vulvovaginal atrophy will depend on the underlying etiology and might include 
individualized treatment. A number of forms of vaginal estrogen and manner of delivery are 
currently available to treat moderate to severe dyspareunia caused by VVA. They all have 
been shown to be effective and are often the preferred treatment due to the targeted efficacy 
for urogenital tissues while resulting in only minimal systemic absorption. Both healthcare 
professionals and patients often find it difficult to broach the subject of sexual problems associated 
with VVA. However, with minimal effort to initiate a conversation about these problems, health-
care providers can provide useful information to their postmenopausal patients in order to help 
them each choose the optimal treatment for their needs and symptoms.
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Introduction
In 2009, most women will live more than one third of their lives after menopause. 
Many of these women, who expect to maintain their health and good quality of life over 
their postmenopausal decades, consider sexual health to be of paramount importance. 
Although hot flashes are the most commonly identified hallmark of menopause and 
aging, many women also suffer with a constellation of vulvovaginal symptoms as a 
result of lowered estrogen. Further, while hot flashes will likely subside over time, 
regardless of whether estrogen therapy (ET) is used, vulvovaginal symptoms are char-
acteristically progressive and unlikely to resolve without treatment.1 It is estimated that 
10% to 40% of postmenopausal women experience discomfort due to vulvovaginal 
atrophy that requires treatment, but only 25% of these women seek treatment.1
Vulvar and vaginal atrophic changes along with dryness burning and irritation of 
the vaginal and vulvar lining can be severe and debilitating enough to affect not only 
a woman’s personal comfort in her daily activities but also her ability to have pleasur-
able pain-free sexual intercourse. Approximately 40% of women with vaginal atrophy 
report dyspareunia.1 Dyspareunia is defined as persistent, recurrent urogenital pain 
occurring before, during, or after sexual intercourse (or penetration). As a result, these 
symptomatic women, who consider sexuality to be an important component to perceived 
quality of life,2,3 are not achieving the quality of life they hope for and expect.International Journal of Women’s Health 2009:1 106
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Maintaining sexual health falls under the purview of 
healthcare providers, particularly those who specialize in 
reproductive medicine. In 2000, an international meeting 
organized by the World Health Organization (WHO) and 
the Pan American Health Organization (PAHO) resulted in 
the publication of a document entitled “Promotion of Sexual 
Health”.4 According to this document, health professionals 
are required to obtain adequate training in human sexuality: 
“Health professionals specializing in reproductive health should 
have a more in-depth training in human sexuality issues than 
the general health practitioner”.4 Despite this mandate, many 
healthcare providers have failed to recognize and address the 
importance of these medical health issues and are not assess-
ing these vulvovaginal symptoms in postmenopausal women. 
Personal embarrassment and time constraints are often cited as 
the common reasons for not addressing sexual concerns. Their 
patients are continuing to suffer painful ramifications of vulvar 
and vaginal atrophy and experiencing painful intercourse. 
Further, they are unaware of restorative treatments available, 
and often feel as if they must endure in distressing silence.
The purpose of this article is to discuss considerations 
in the diagnosis and management of VVA that results in 
dyspareunia, focusing on the use of local ET. While local ET 
is one of the most effective and widely available treatment 
options for postmenopausal vulvovaginal atrophy (VVA), it 
is requested by and/or offered to a relatively small number 
of postmenopausal women.1
Vulvovaginal symptoms resulting 
from declining endogenous estrogen
With the decrease in endogenous production of estrogen as 
a result of menopause, either natural or surgically induced, 
tissues can become atrophic. Estradiol, the primary form of 
estrogen produced by a woman’s ovary during her reproduc-
tive years, plays an essential role in maintaining the elasticity 
and health of her genital tissues. Declining levels increase 
tissue fragility and the risk for vaginal and urinary infections, 
irritation, dryness, urogenital pain, and the probability of 
vaginal tissue trauma.5,6 Atrophic vulvovaginitis is charac-
terized by genital mucosa that has compromised elasticity, 
decreased moisture, and compromised integrity as well as 
tissue erythema and inflammation.7,8
It does not take long for the effects of estrogen insufficiency 
to surface, symptoms often occurring within 12 months of 
the cessation of menstruation, either as a result of natural or 
surgical menopause. These symptoms also re-occur within 
12 months of discontinuation of postmenopausal hormone 
therapy.9 Atrophy associated dyspareunia is often associated 
with the sexual distress and other complaints of sexual 
dysfunction.10,11 Reactive lowered desire is common as well 
as direct impact on the marital relationship.
Table 1 lists the estrogen-deficient atrophic changes that 
results from tissue that cannot remain lubricated. This tissue 
is at risk for damage during sexual penetration or intercourse 
and therefore may lead to dyspareunia.5,6,8,12,13
Physical examination
In addition to obtaining a thorough history including general 
medical, surgical, family, lifestyle, gynecologic and sexual 
history, a comprehensive pelvic examination of the vulva and 
vagina should be completed. This exam may reveal signs of 
vulvovaginal atrophy such as:
•  Appearance of hypopigmented, smooth, non-elastic, thin 
and/or shiny epithelium;
•  Thinning or sparse pubic hair;
•  Patchy erythema;
•  Introital contractures/involution;
•  Labial fusion or decreased size and integrity;
•  Plaques;
•  Clitoral shrinkage; retracted prepuce which can expose 
the clitoris to trauma;
•  Petechiae and/or microfissures may also be present if 
atrophy has progresses for months or years and has not 
been treated.9,12,15
Laboratory testing may also provide evidence of atrophy. 
Vaginal pH testing exceeding pH 5.0 can be an indication 
of estrogen deprivation. Further, microscopy, which may 
show bacterial and/or fungal growth; and/or a vaginal 
maturation index (VMI) which shows increased ratios of 
intermediate and parabasal cells compared to superficial 
cells can provide confirmation of physical examination 
findings.6,15 These diagnostic tests may also act to exclude 
Table 1 Atrophic changes associated with estrogen loss
• vaginal canal shortens and narrows
•  Decline in the quantity and quality of vaginal secretions
•  Decline in collagen, adipose and water-retaining ability of vulva
•   vaginal walls become thinner, less elastic, and pale with loss  
of rugation
•   vaginal surface becomes friable with petechiae, ulcerations, and bleed-
ing often occurring after minimal trauma (as this cycle is repeated, 
adhesions may develop between touching surfaces)
•    Prepuce of the clitoris atrophies, and the clitoris loses its protective 
covering and is more easily irritated
reprinted with permission from Mehta A, Bachmann G.   vulvovaginal complaints. Clin Obstet 
Gynecol. 2008;51(3):549–555.14 Copyright © 2008   Wolters Kluwer Health.International Journal of Women’s Health 2009:1 107
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other possible causes of vulvovaginal atrophy that is not 
menopause related such as infection, other hypoestrogenic 
states, allergic reaction, trauma, benign and malignant tumors 
or other medical conditions.1 Some sexual medicine experts 
advocate the addition of vulvoscopy to the diagnositic work 
up of a woman suffering from painful intercourse. The impor-
tance to rule out underlying vulvar pathology including but 
not limited to lichen sclerosus, lichen planus and potential 
malignant morphological changes is important as the vuvlar 
symptomology can mimic many dermatological conditions.
Treatment
The main goals of treatment for vaginal atrophy are to 
improve symptoms and to restore vaginal and vulvar ana-
tomic changes.1 Treatment choices for postmenopausal 
dyspareunia resulting from vulvovaginal atrophy will depend 
on the underlying etiology and might include individualized 
treatment of inflammatory conditions, improving vulvar 
hygiene, educational guidance and lifestyle modification.14 
The NAMS position statement on the role of local vaginal 
estrogen asserts that non-hormonal lubricants and moistur-
izers in combination of regular sexual activity should be 
considered first-line therapies. Many times women find 
these products inadequate. Moisturizers and lubricants can 
contain additives including colors, flavors, bactericides 
and spermacides, which may affect epithelial integrity. 
If symptomatology is unresolved, then prescription minimally 
absorbed local vaginal ET may be considered.1 For VVA that 
is the result of a hypoestrogenic state (ie, postmenopause), 
treatment is likely to be supplementation of estrogen using 
either exogenous systemic or local estrogen. It is also 
important to note that in the new era of minimal dose for 
shortest time for systemic hormone therapy, the newer lower 
doses do not preclude atrophic vaginal symptomatology. 
It is estimated that up to 10% of women on new lower dose 
systemic hormones suffer from atrophic vaginal symptoms 
and may benefit from local therapy. However, exogenous 
systemic estrogen may be medically contraindicated 
(or simply unwanted) in some women leaving local vaginal 
estrogen treatment as the most suitable option. A Cochrane 
Review of local estrogens for vaginal atrophy shows that 
vaginally administered ET significantly improves vaginal 
cytomorphology and atrophic vaginal symptoms.16 Local 
hormone therapy (Table 2) has been approved by the US 
Food and Drug Administration for use in moderate to severe 
vulvovaginal atrophy, dyspareunia, vasomotor symptoms 
and osteoporosis prevention.17 Current practice recommen-
dations from professional organizations including the North 
American Menopause Society (NAMS) and The American 
College of Obstetrics and Gynecology (ACOG) advise 
that treatment choices should be individualized and that 
moderate to severe symptoms of VVA be treated with the 
lowest effective dose of ET for the shortest amount of time 
to achieve and maintain satisfactory results.1,18,19
Selecting a treatment option
In a health care environment, patient choices are often 
affected by the influences of other individuals. This occurs 
when information is given to patients by health care 
professionals, associates or other family members who all 
have their own treatment experiences and opinions. Decision 
making is further complicated by patient characteristics and 
their perception of control over the treatment plan and how 
important this control is to her. Others maybe influenced 
by the media, public opinion or concern over potential 
malignancy. Satisfaction with a decision is maximized when 
there is congruence between the ultimate preference of the 
patient and the actual treatment chosen. Therefore, it is 
important to provide not only the best treatments available, 
but also to assist a patient in making the best possible choices 
for her own unique circumstances.20 In recent studies, 
postmenopausal women report the greatest satisfaction 
Table 2 vaginal estrogen therapy for postmenopausal use in the United States1
Composition Product name Dosing
vaginal creams 17β-estradiol 
conjugated estrogens (formerly 
conjugated equine estrogens)
estrace®   vaginal Cream 
Premarin®   vaginal Cream
Initial: 2–4 g/d for 1–2 wk  
Maintenance: 1 g/d (0.1 mg active ingredient/g)  
0.5–2 g/d (0.625 mg active ingredient/g
vaginal rings 17β-estradiol estring® Device containing 2 mg releases 7.5 µg/d for 90 d
vaginal tablet estradiol hemihydrate vagifem® Initial: 1 tablet/d for 2 wk  
Maintenance: 1 tablet twice/wk (tablet containing 25.8 µg 
estradiol hemihydrate equivalent to 25 µg of estradiol)
Modified from the role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause 
Society. Menopause. 2007;14(3):357–369.1 Copyright © 2007 Wolters Kluwer Health.International Journal of Women’s Health 2009:1 108
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with VVA treatment when they were actively involved in 
decision making and when they perceived that their health 
care professionals were well informed, unbiased and well 
educated about treatment options.21–24 As noted above, first-
line management for VVA should include non-hormonal 
vaginal lubricants and moisturizers (Table 3) and if ineffective 
then options include several forms of local therapy. After 
being fully educated about the available choices (Tables 2 
and 3), a woman and her healthcare provider can develop a 
treatment plan which reflects her goals for and comfort level 
with varying therapeutic options.
Lubricants and moisturizers
Vaginal lubricants can be a treatment option for women 
who require additional lubrication (ie, water-soluble jelly 
or water-based gel) in order to avoid discomfort specifi-
cally during sexual activity. These lubricants can be used 
externally on the labia or clitoris, at the vaginal opening or 
on a penis or other object intended for insertion in order to 
facilitate intromission (Table 3). The effectiveness of these 
types of products can be supplemented by the addition 
of intravaginal moisturizers (ie, polycarbophil; oil-based 
capsules) which are inserted into the vagina 1 to 2 times 
weekly to keep the vagina moist and pH balanced on a daily 
basis. While these vaginal lubricants and moisturizers are 
reasonable first-line therapies for VVA, their effectiveness 
in resolving vulvovaginal irritation is adequate only 
while they are on the tissue and may not be adequate to 
resolve VVA symptoms.1,7,15 Some women complain of 
increased symptomatology with these products as they 
can be irritants. Others find them messy, inconvenient 
and expensive. Additives should be used with caution 
and the postmenopausal woman should exercise caution 
when considering a moisturizer or lubricant that contains 
bactericides, spermicides, warming or other enhancers; 
these maybe problematic for the sensitive epithelium.
Minimally absorbed vaginal 
estrogen therapies
A number of forms of vaginal estrogen and manner of 
delivery are currently available to treat moderate to severe 
dyspareunia caused by VVA. They all have been shown to 
be effective and are often the preferred treatment because 
of the targeted efficacy for urogenital tissues while resulting 
in only minimal systemic absorption, and thus potentially 
reducing exposure of estrogen to breast and endometrium 
tissue compared to systemic ET. Vaginal estrogen is currently 
available in several modalities:
•  A 25.8 µg micronized estradiol hemihydrate vaginal 
tablet (Vagifem®; Novo Nordisk Inc). Newer lowered 
dose of 10 µg have also been shown effective in treating 
vaginal atrophy
•  3 month sustained-release silastic ring which contains 
2 mg micronized estradiol and 75 µg of estradiol every 
24 hours (Estring®; Pfizer)
•  Creams: Estradiol Cream (Estrace®; Warner Chilcott 
Laboratories), a conjugated estrogen cream (Premarin® 
Vaginal Cream, 0.625 mg CE/g; Wyeth Pharmaceuticals 
Inc.,) with a newly approved low-dose formulations of 
0.5 g biweekly conjugated estrogen cream (biweekly) 
for the specific indication of moderate to severe 
dyspareunia.
All three forms of local estrogen have been shown to be 
equally effective in reducing the subjective symptoms of 
vaginal atrophy (dryness, irritation and dyspareunia).1
Minimally absorbed local vaginal ETs have been associated 
with lower risks of adverse events compared with systemically 
acting oral formulations of ET. Local ET may also provide 
Table 3 Types of lubricants
Base Ingredients Safe with latex? Staining? Comments
Water Deionized water, glycerin, 
propylene glycol
Yes No rarely causes irritation but 
dries out with extended activity
Petroleum Mineral oil, petroleum jelly, 
baby oil
No; do not use with 
condoms, diaphragms, 
or cervical caps
Yes Irritating to vagina
Natural oil Avacado, olive, peanut, corn Yes Yes Safe (unless peanut allergy) and 
nonirritating to vagina
Silicone Silicone polymers Yes No Nonirritating to 
vagina, long-lasting and 
waterproof
reproduced with permission from Hutcherson HY, Kingsberg SA, Krychman ML, et al.   A positive approach to female sexual health: A summary report. Female Patient. 
2009;(Suppl  April):1–6.25 Copyright © 2009 Quadrant Health Com Inc.International Journal of Women’s Health 2009:1 109
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some relief of menopause-associated symptoms such as hot 
flushes, night sweats and sleep disturbances.16,24,27–29
Most women, including both naturally menopausal and 
women with surgically induced menopause, will experience 
relief of vaginal atrophy symptoms within the first few weeks 
of starting therapy, although complete restoration of genital 
tissue integrity and comfort may take up to 4 to 6 weeks. 
Since the use of restorative therapy for VVA and resulting 
dyspareunia may be necessary for several years, use of local 
minimally absorbed estrogen over time may be preferable 
to systemic therapy (which has also been approved for the 
treatment of VVA).1
Safety
A Cochrane review of local estrogen options reported no 
significant differences among them in terms of endometrial 
thickness, hyperplasia or percentage of adverse events.16 
The most frequent reported adverse effects associated with 
vaginal ET are vaginal bleeding and breast pain. However, 
research suggests that the incidences of these adverse events, 
endometrial proliferation or hyperplasia (assessed by direct 
sampling) are very low over 12 months.23–31 Since there is 
lack of very long term safety data for vaginal ET, in cases 
where a woman is having symptoms such as spotting or 
breakthrough bleeding, a complete evaluation including 
endometrial sampling and transvaginal ultrasound should be 
done. Undiagnosed vaginal bleeding should be completely 
assessed and evaluated. The addition of progesterone to 
a woman with a uterus solely on minimally applied local 
estrogen products remains controversial.
Invariably the question arises as to whether it is safe to 
use local estrogen treatment in cancer survivors. This is a 
particularly difficult but hugely important question to address 
because many cancer survivors, regardless of the type of 
cancer, suffer from VVA either caused by chemotherapy, the 
chemically induced menopause caused by the chemotherapy, 
surgically induced menopause due to removal of the ovaries, 
radiation side-effects or other treatment effects. The use of 
minimally absorbed local estrogen products has not been 
sufficiently studied for long-term safety in women with 
hormonally sensitive tumors. However, their use can be 
implemented in women without hormone sensitive tumors. 
Since women and healthcare professionals alike are extremely 
sensitized to the topic of estrogen and cancer, the option 
is often dismissed without any discussion. Individualized 
assessment and a detailed discussion of the potential risks 
and benefits should always occur between a postmenopausal 
cancer survivor and her healthcare provider.
Strategies for evaluating complaints 
of dyspareunia
Regardless of how brief or how detailed the initial 
assessment, a number of communication strategies and skills 
will enhance the efficiency and accuracy of diagnosis and 
treatment suggestions.
Many healthcare professionals find that the most difficult 
part of assessing sexual concerns is to know how, when 
and where to address the topic. Establishing rapport and 
putting patients at ease are critical first steps and, in general 
help to improve overall patient satisfaction. The healthcare 
professional sets the tone for the conversation. Therefore if 
he/she is comfortable and at ease with sexual terminology and 
content then patients are more likely to also feel comfortable 
reporting their sexual concerns.
In a realistic attempt to encourage all practitioners to 
address sexual function in their patients, even the most basic 
assessment can be useful and can be limited to a minimal 
number of specific questions with minimal time involvement. 
Opening the topic by mentioning the importance of assessing 
sexual function as part of your usual history and physical 
with all patients may put patients at ease. Then simply 
asking 1 or 2 questions about her genital and sexual health 
will be sufficient to begin a dialogue. For example, one 
can ask a general question such as “what concerns to you 
have about your genital or sexual health would you like to 
talk about?” – or a more targeted question such as “are you 
experiencing any pain, burning or itching associated with 
sexual activity?”7,8
Elements to include when 
evaluating dyspareunia
Table 4 lists questions that will help identify the essential 
components of a sexual complaint. These questions 
Table 4 Questions to include in a sexual assessment32–34
How does the patient describe the problem?
How long has the problem been present?
Was the onset sudden or gradual?
Is the problem specific to a situation/partner or is it generalized?
Were there likely precipitating events (biologic or situational)?
Are there problems in the woman’s primary sexual relationship (or any 
relationship in which the sexual problem is occurring)?
Are there current life stressors that might be contributing to sexual 
problems?
Are there problems in desire, arousal or orgasm?
Does the partner have any sexual problems?International Journal of Women’s Health 2009:1 110
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help draw out the patient’s perceptions of the problem, 
the timeline, and current health problems that might 
be affecting sexual function. These questions also help 
identify which components of the sexual response or 
other areas of function are compromised by pain. This 
information can help determine etiology and provide 
the basis for treatment considerations (eg, education, 
psychotherapy, medication).
Conclusion
Healthcare professionals can no longer claim lack of 
available approved treatments as an excuse for avoiding the 
discussion of vulvovaginal atrophy and dyspareunia with 
their patients. Those clinicians who are well informed about 
the causes and treatment options are in the best position to 
comfortably and efficiently initiate a conversation about 
these problems. They can then provide useful information 
to their postmenopausal patients in order to help them each 
choose the optimal treatment for their needs and symptoms 
which take into account a patient’s medical history, 
perceived quality of life and other relevant individualized 
information.
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